Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 11 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

18%

2 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2

7(77.8%)

Phase 4

1(11.1%)

Phase 3

1(11.1%)

9Total

Phase 2(7)

Phase 4(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (11)

Showing 11 of 11 trials

NCT05644262Phase 2Active Not Recruiting

Life's End Benefits of cannaBidiol and tetrahYdrocannabinol

Role: collaborator

NCT07173803Phase 2Not Yet Recruiting

The Progressive Supranuclear Palsy Clinical Trial Platform

Role: collaborator

NCT07264283Phase 2Not Yet Recruiting

The Progressive Supranuclear Palsy Clinical Trial Platform - Regimen B: LM11A-31

Role: collaborator

NCT07217665Phase 2Not Yet Recruiting

The Progressive Supranuclear Palsy Clinical Trial Platform - Regimen A: AADvac1

Role: collaborator

NCT04468659Phase 3Active Not Recruiting

AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid

Role: collaborator

NCT06957418Phase 2Not Yet Recruiting

Alzheimer's Tau Platform: Master Protocol

Role: collaborator

NCT07167966Phase 2Not Yet Recruiting

Alzheimer's Tau Platform: Regimen A - AADvac1

Role: collaborator

NCT06911944Phase 4Not Yet Recruiting

Amyloid Lowering for Alzheimer's in Down's With Donanemab Investigation

Role: collaborator

NCT05531656Phase 2Active Not Recruiting

A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease